Der Ophthalmologe

, Volume 110, Issue 8, pp 783–794 | Cite as

Neuritis nervi optici

CME Zertifizierte Fortbildung

Zusammenfassung

Die Neuritis nervi optici ist eine der wichtigsten Differenzialdiagnosen der akuten Sehverschlechterung im jungen und mittleren Erwachsenenalter. Die Diagnose wird klinisch gestellt. Die funktionelle Prognose der Erkrankung ist grundsätzlich gut. Steroide verkürzen das Erholungsintervall, ändern jedoch nichts an der funktionellen Langzeitprognose. Wichtigste Untersuchung zur Abschätzung eines möglichen Multiple-Sklerose-Risikos ist die Magnetresonanztomographie. Die optische Kohärenztomographie liefert zusätzliche Hinweise auf Verlauf und Funktion nach Neuritis nervi optici und kann in Zukunft vielleicht weitere Zusammenhänge zwischen Neuritis nervi optici und evtl. multipler Sklerose liefern.

Schlüsselwörter

Multiple Sklerose Optische Kohärenztomographie Sehverschlechterung Steroide Magnetresonanztomographie 

Abkürzungsverzeichnis

MRT

Magnetresonanztomographie

MS

multiple Sklerose

NNO

Neuritis nervi optici

OCT

optische Kohärenztomographie

VEP

visuell evozierte Potenziale

Optic nerve neuritis

Abstract

Optic nerve neuritis is one of the most important differential diagnoses of visual loss in young and middle aged adults. The prognosis in terms of functional outcome is generally good. The diagnosis of optic neuritis is clinical. Steroids can reduce the recovery time but do not affect the long-term functional outcome. Magnetic resonance imaging (MRI) is the most important investigation for assessing an associated risk of multiple sclerosis. Optical coherence tomography (OCT) contributes additional details on the course and functional outcome of optic neuritis. In the future OCT may additionally contribute to the relationship between optic neuritis and possible associated multiple sclerosis.

Keywords

Multiple sclerosis Visual loss Steroids Optical coherence tomography Magnetic resonance imaging 

Literatur

  1. 1.
    Beck RW (1992) The optic neuritis treatment trial. Implications for clinical practice. Optic Neuritis Study Group. Arch Ophthalmol 110(3):331–332PubMedCrossRefGoogle Scholar
  2. 2.
    Beck RW, Gal RL (2008) Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 126(7):994–995PubMedCrossRefGoogle Scholar
  3. 3.
    Volpe NJ (2008) The optic neuritis treatment trial: a definitive answer and profound impact with unexpected results. Arch Ophthalmol 126(7):996–999PubMedCrossRefGoogle Scholar
  4. 4.
    Roed HG et al (2005) A double-blind, randomized trial of iv immunoglobulin treatment in acute optic neuritis. Neurology 64(5):804–810PubMedCrossRefGoogle Scholar
  5. 5.
    Tselis A et al (2008) Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 15(11):1163–1167PubMedCrossRefGoogle Scholar
  6. 6.
    Comi G et al (2001) Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 357(9268):1576–1582PubMedCrossRefGoogle Scholar
  7. 7.
    Comi G et al (2009) Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 374(9700):1503–1511PubMedCrossRefGoogle Scholar
  8. 8.
    Kappos L et al (2009) Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 8(11):987–997PubMedCrossRefGoogle Scholar
  9. 9.
    Jacobs LD et al (2000) Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 343(13):898–904PubMedCrossRefGoogle Scholar
  10. 10.
    Kinkel RP et al (2006) IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 66(5):678–684PubMedCrossRefGoogle Scholar
  11. 11.
    Wingerchuk DM et al (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815PubMedCrossRefGoogle Scholar
  12. 12.
    Ratchford JN et al (2009) Optical coherence tomography helps differentiate neuromyelitis optica and MS optic neuropathies. Neurology 73(4):302–308PubMedCrossRefGoogle Scholar
  13. 13.
    Costello F et al (2006) Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 59(6):963–969PubMedCrossRefGoogle Scholar
  14. 14.
    Beck RW et al (2003) High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 121(7):944–949PubMedCrossRefGoogle Scholar
  15. 15.
    Henderson AP et al (2010) A preliminary longitudinal study of the retinal nerve fiber layer in progressive multiple sclerosis. J Neurol 257(7):1083–1091PubMedCrossRefGoogle Scholar
  16. 16.
    Petzold A et al (2010) Optical coherence tomography in multiple sclerosis: a systematic review and meta-analysis. Lancet Neurol 9(9):921–932PubMedCrossRefGoogle Scholar
  17. 17.
    Naismith RT et al (2009) Optical coherence tomography is less sensitive than visual evoked potentials in optic neuritis. Neurology 73(1):46–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  1. 1.Schielbehandlung und NeuroophthalmologieUniversitäts-Augenklinik WürzburgWürzburgDeutschland

Personalised recommendations